FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2276596278> ?p ?o ?g. }

• W2276596278 endingPage "811" @default.
• W2276596278 startingPage "803" @default.
• W2276596278 abstract "and objectives The Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes 3:4 study demonstrated a significant beneficial effect of the vasopressin V2 receptor antagonist tolvaptan on rates of kidney growth and eGFR decline in autosomal dominant polycystic kidney disease (ADPKD). This post hoc analysis was performed to reassess the primary and secondary efficacy endpoints by CKD stage at baseline.In a phase 3, multicenter, double-blind, placebo-controlled, 3-year trial, 1445 patients with ADPKD (age 18-50 years), with total kidney volume (TKV) ≥750 ml and estimated creatinine clearance ≥60 ml/min, were randomly assigned 2:1 to split-dose tolvaptan (45/15, 60/30, or 90/30 mg daily as tolerated) or placebo. The primary endpoint was annualized rate of TKV change. Secondary endpoints included a composite endpoint of time to multiple composite ADPKD-related events (worsening kidney function, kidney pain, hypertension, and albuminuria) and rate of kidney function decline.Tolvaptan reduced annualized TKV growth by 1.99%, 3.12%, and 2.61% per year (all P<0.001; subgroup-treatment interaction, P=0.17) and eGFR decline by 0.40 in CKD1 (P=0.23), 1.13 in CKD2 (P<0.001) and 1.66 ml/min per 1.73 m(2) per year in CKD3 (P<0.001) with a trend for a positive subgroup-treatment interaction (P=0.07) across CKD1, CKD2 and CKD3. ADPKD-related events were less frequent in tolvaptan recipients than in placebo recipients among those with CKD1 (hazard ratio [HR], 0.83; 95% confidence interval [95% CI], 0.70-0.98; P=0.03) and those with CKD 3 (HR, 0.71; 95% CI, 0.57-0.89; P=0.003), but not among those with CKD2 (HR, 1.02; 95% CI, 0.85-1.21; P=0.86). Aquaresis-related adverse events (more frequent in the tolvaptan group) and ADPKD-related adverse events (more frequent in the placebo group) were not associated with CKD stage. Hypernatremia events in tolvaptan-treated patients with CKD3 and plasma aminotransferase elevations in tolvaptan-treated patients across CKD stages 1-3 occurred more frequently than in placebo recipients.This post hoc analysis suggests clinically similar beneficial effects of tolvaptan in ADPKD across CKD stages 1-3." @default.
• W2276596278 created "2016-06-24" @default.
• W2276596278 creator A5001840552 @default.
• W2276596278 creator A5011537086 @default.
• W2276596278 creator A5016444110 @default.
• W2276596278 creator A5033193895 @default.
• W2276596278 creator A5033792420 @default.
• W2276596278 creator A5051197194 @default.
• W2276596278 creator A5060745225 @default.
• W2276596278 creator A5068436990 @default.
• W2276596278 creator A5070149489 @default.
• W2276596278 creator A5085269683 @default.
• W2276596278 date "2016-02-23" @default.
• W2276596278 modified "2023-10-14" @default.
• W2276596278 title "Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial" @default.
• W2276596278 cites W1894300850 @default.
• W2276596278 cites W2001771261 @default.
• W2276596278 cites W2013620388 @default.
• W2276596278 cites W2014786231 @default.
• W2276596278 cites W2016547342 @default.
• W2276596278 cites W2043524463 @default.
• W2276596278 cites W2045181376 @default.
• W2276596278 cites W2052771648 @default.
• W2276596278 cites W2064249981 @default.
• W2276596278 cites W2073742622 @default.
• W2276596278 cites W2078374899 @default.
• W2276596278 cites W2082246284 @default.
• W2276596278 cites W2097584753 @default.
• W2276596278 cites W2103621765 @default.
• W2276596278 cites W2107890949 @default.
• W2276596278 cites W2112643254 @default.
• W2276596278 cites W2123000903 @default.
• W2276596278 cites W2130729770 @default.
• W2276596278 cites W2143108257 @default.
• W2276596278 cites W2154921342 @default.
• W2276596278 cites W2157314032 @default.
• W2276596278 cites W2162966061 @default.
• W2276596278 cites W2169096913 @default.
• W2276596278 doi "https://doi.org/10.2215/cjn.06300615" @default.
• W2276596278 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4858477" @default.
• W2276596278 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26912543" @default.
• W2276596278 hasPublicationYear "2016" @default.
• W2276596278 type Work @default.
• W2276596278 sameAs 2276596278 @default.
• W2276596278 citedByCount "112" @default.
• W2276596278 countsByYear W22765962782016 @default.
• W2276596278 countsByYear W22765962782017 @default.
• W2276596278 countsByYear W22765962782018 @default.
• W2276596278 countsByYear W22765962782019 @default.
• W2276596278 countsByYear W22765962782020 @default.
• W2276596278 countsByYear W22765962782021 @default.
• W2276596278 countsByYear W22765962782022 @default.
• W2276596278 countsByYear W22765962782023 @default.
• W2276596278 crossrefType "journal-article" @default.
• W2276596278 hasAuthorship W2276596278A5001840552 @default.
• W2276596278 hasAuthorship W2276596278A5011537086 @default.
• W2276596278 hasAuthorship W2276596278A5016444110 @default.
• W2276596278 hasAuthorship W2276596278A5033193895 @default.
• W2276596278 hasAuthorship W2276596278A5033792420 @default.
• W2276596278 hasAuthorship W2276596278A5051197194 @default.
• W2276596278 hasAuthorship W2276596278A5060745225 @default.
• W2276596278 hasAuthorship W2276596278A5068436990 @default.
• W2276596278 hasAuthorship W2276596278A5070149489 @default.
• W2276596278 hasAuthorship W2276596278A5085269683 @default.
• W2276596278 hasBestOaLocation W22765962781 @default.
• W2276596278 hasConcept C126322002 @default.
• W2276596278 hasConcept C126894567 @default.
• W2276596278 hasConcept C142724271 @default.
• W2276596278 hasConcept C159641895 @default.
• W2276596278 hasConcept C168563851 @default.
• W2276596278 hasConcept C203092338 @default.
• W2276596278 hasConcept C204787440 @default.
• W2276596278 hasConcept C207103383 @default.
• W2276596278 hasConcept C27081682 @default.
• W2276596278 hasConcept C2776174234 @default.
• W2276596278 hasConcept C2776266639 @default.
• W2276596278 hasConcept C2776370428 @default.
• W2276596278 hasConcept C2778653478 @default.
• W2276596278 hasConcept C2780091579 @default.
• W2276596278 hasConcept C2780306776 @default.
• W2276596278 hasConcept C2780615674 @default.
• W2276596278 hasConcept C44249647 @default.
• W2276596278 hasConcept C67761136 @default.
• W2276596278 hasConcept C71924100 @default.
• W2276596278 hasConceptScore W2276596278C126322002 @default.
• W2276596278 hasConceptScore W2276596278C126894567 @default.
• W2276596278 hasConceptScore W2276596278C142724271 @default.
• W2276596278 hasConceptScore W2276596278C159641895 @default.
• W2276596278 hasConceptScore W2276596278C168563851 @default.
• W2276596278 hasConceptScore W2276596278C203092338 @default.
• W2276596278 hasConceptScore W2276596278C204787440 @default.
• W2276596278 hasConceptScore W2276596278C207103383 @default.
• W2276596278 hasConceptScore W2276596278C27081682 @default.
• W2276596278 hasConceptScore W2276596278C2776174234 @default.
• W2276596278 hasConceptScore W2276596278C2776266639 @default.
• W2276596278 hasConceptScore W2276596278C2776370428 @default.
• W2276596278 hasConceptScore W2276596278C2778653478 @default.
• W2276596278 hasConceptScore W2276596278C2780091579 @default.

• next